| Literature DB >> 28878123 |
Rohit Gaurav1, Jason T Varasteh1, Michael R Weaver1, Sean R Jacobson1, Laura Hernandez-Lagunas2, Qing Liu3, Eva Nozik-Grayck2, Hong Wei Chu1, Rafeul Alam1, Børge G Nordestgaard4,5, Camilla J Kobylecki4, Shoaib Afzal4,5, Geoffrey L Chupp3, Russell P Bowler1.
Abstract
Oxidative stress is important in the pathogenesis of allergic asthma. Extracellular superoxide dismutase (EC-SOD; SOD3) is the major antioxidant in lungs, but its role in allergic asthma is unknown. Here we report that asthmatics have increased SOD3 transcript levels in sputum and that a single nucleotide polymorphism (SNP) in SOD3 (R213G; rs1799895) changes lung distribution of EC-SOD, and decreases likelihood of asthma-related symptoms. Knockin mice analogous to the human R213G SNP had lower airway hyperresponsiveness, inflammation, and mucus hypersecretion with decreased interleukin-33 (IL-33) in bronchoalveolar lavage fluid and reduced type II innate lymphoid cells (ILC2s) in lungs. SOD mimetic (Mn (III) tetrakis (N-ethylpyridinium-2-yl) porphyrin) attenuated Alternaria-induced expression of IL-33 and IL-8 release in BEAS-2B cells. These results suggest that R213G SNP potentially benefits its carriers by resulting in high EC-SOD in airway-lining fluid, which ameliorates allergic airway inflammation by dampening the innate immune response, including IL-33/ST2-mediated changes in ILC2s.Entities:
Keywords: Asthma; Drug therapy; Inflammation; Innate immunity; Pulmonology
Mesh:
Substances:
Year: 2017 PMID: 28878123 PMCID: PMC5621928 DOI: 10.1172/jci.insight.95072
Source DB: PubMed Journal: JCI Insight ISSN: 2379-3708